Cardiovascular Journal of Africa: Vol 29 No 6 (November/December 2018)

2 / 74

PHARMA DYNAMICS CLOPIDOGREL 75 mg. Each tablet contains 75 mg clopidogrel. S3 A42/8.2/0128. NAM NS2 10/7.1/0377. For full prescribing information, refer to the package insert approved by the Medicines Control Council,
October 2008. 1) Database of Medicine Prices (14 March 2017). Department of Health website. - Accessed on 30 March 2017. 2) Poponina TM, et al. Current approaches to the prevention of thrombotic
complications in patients with acute coronary syndrome without ST-segment elevation. Topical issues of heart and vascular diseases. 2009;4:4-9. (English translation) 3) Creager MA. Results of the CAPRIE trial: efficacy and
safety of clopidogrel. Vascular Medicine 1998;3:257-260. 4) COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. The Lancet
2005;366(9497):1607-1621. 5) Sabatine MS, et al. Addition of Clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New England Journal of Medicine 2005;352:1179-89. 6) The CURE Trial
Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345:494-502. PDCLD395/04/2017.
For further product information contact PHARMA DYNAMICS P O Box 30958 Tokai Cape Town 7966
Tel 021 707 7000 Fax 021 701 5898 Email CUSTOMER CARE LINE 0860 PHARMA (742 762)
Shown to reduce the risk of atherosclerotic events
in a wide range of patients with a history of:
• Stroke3,4,6
• PAD3
• STEMI4,5
• Unstable Angina/NSTEMI6
cost e ective1,
clinically proven2 reduction
of atherosclerotic events